SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Photo of female scientist using microscope
Job Trends
9 Companies Hiring in Oncology
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
October 9, 2025
 · 
2 min read
 · 
Angela Gabriel
People determined to be free, freedom and confinement vector art
Rare diseases
Nearly Three Quarters of FDA Breakthrough Designated Drugs Win Approval: Report
New analysis from Jefferies shows that rare disease and cancer drugs granted the status are especially likely to be approved.
October 9, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Golden game piece with crown as a leader a group of golden game pieces - 3D illustration
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.
October 8, 2025
 · 
2 min read
 · 
Annalee Armstrong
Modern design with a positive context, a handshake. Concept of help, support and harmony between adults. Modern art collage, trendy magazine style.
Mergers & acquisitions
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
The centerpiece of the deal is orelabrutinib, a BTK inhibitor in late-stage development for multiple sclerosis that Biogen once paid $125 million for but abandoned after less than two years of testing.
October 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boehringer Ingelheim sign on a building/
Approvals
Boehringer Ingelheim Breaks Decade-Long Approval Drought in Idiopathic Pulmonary Fibrosis
In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.
October 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Messenger RNA or mRNA strand 3D rendering illustration with copy space. Genetics, science, medical research, genome replication concepts.
Government
Despite mRNA Vaccine Pullback, HHS Awards $48M for Kernal’s mRNA CAR T Program
The $48 million award, granted through the Advanced Research Projects Agency for Health, will help Kernal take its in vivo mRNA-encoded CAR T therapy forward.
October 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
The U.S. government remains shut down, with the FDA closed for new drug applications until further notice; cell and gene therapy leaders gather for the annual meeting in Phoenix with the field in a state of flux; Pfizer and Amgen will make drugs available at a discount as President Donald Trump’s tariffs still loom; and new regulatory documents show how Pfizer beat out the competition for Metsera.
October 8, 2025
 · 
1 min read
 · 
Heather McKenzie
Abstract illustration of targeting cancer cell made of glowing neon particles. Blue geometric background depicting cancer cell screening and disease treatment medical concept. Digital vector illustration
Cell therapy
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.
October 8, 2025
 · 
2 min read
 · 
Annalee Armstrong
3D collage design composite trend artwork sketch of different routeway direction target trader young lady back walk step success choice.
C-suite
The 5 Most Powerful Women in Biopharma
As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the industry’s smaller biopharmas.
October 8, 2025
 · 
6 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS